SOPHiA GENETICS has launched MSK-ACCESS® powered with SOPHiA DDM™!
This decentralized version of the highly validated liquid biopsy assay developed and routinely used by Memorial Sloan Kettering Cancer Center (MSK) uses a matched tumor-normal approach to reduce noise and the risk of biological false positives. By combining MSK’s clinical expertise in cancer genomics and the robust algorithms of the SOPHiA DDM™ Platform, we can support laboratories worldwide with their precision cancer analysis capabilities.
Learning Objectives:
Understand the advantages of using a matched tumor-normal approach to reduce noise and the risk of biological false positives.
Learn about the clinical implementation and benefits of MSK-ACCESS® at MSK and its evolution from version 1 to the expanded version 2.
Explore the analytical concordance data of MSK-ACCESS® powered with SOPHiA DDM™ for liquid biopsy.
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
